Roth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsInitiationPrice Target
Roth Capital analyst Adam Walsh initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $113.
Roth Capital analyst Adam Walsh initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $113.